Anixa Biosciences

Anixa BiosciencesAnixa is a biotechnology company developing a range of programs targeting cancer and infectious diseases. Anixa's coronavirus disease treatment program includes a novel immunotherapy approach that utilizes a new type of CAR-T, called Chimeric Endocrine Receptor T-cell (Cel-T) technology, and a COVID-19 treatment strategy focused on inhibiting the function of certain viral proteins. Anixa’s vaccine portfolio includes immunotechnology targeting specific "retired" proteins associated with breast cancer, particularly Triple-Negative Breast Cancer (TNBC) and ovarian cancer.